Skip to main content
. 2015 May 12;36(1):173–185. doi: 10.3892/ijmm.2015.2207

Figure 5.

Figure 5

The glucagon-like peptide-1 receptor (GLP-1R) signaling agonist, liraglutide, attenuates lipotoxicity-induced islet dysfunction. Isolated non-diabetic islets were pre-treated with 100 nmol/l liraglutide and/or 0.5 µmol/l exendin-(9-39) for 2 h, followed by exposure to 0.5 mmol/l palmitate for 48 h. Islet (A) viability (detected by MTT assay) and (B) apoptosis (determined by examining histone-associated DNA fragments), and (C) pancreatic duodenal homeobox 1 (PDX1) mRNA levels (detected by qPCR). n=3 separate islet preparations. (D) After 8 weeks on their respective diets, the mRNA expression of PDX1, glucose transporter 2 (GLUT2) and Nkx6.1 was detected in the pancreata of the mice. (E) The plasma insulin levels were detected by insulin enzyme-linked immunosorbent assay (ELISA). n=6–7 mice/group; *p<0.05; **p<0.01; ***p<0.001.